UK markets close in 4 hours 28 minutes

AMGN Jan 2025 160.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
119.650.00 (0.00%)
As of 12:12PM EDT. Market open.
Full screen
Previous close119.65
Open119.65
Bid117.10
Ask121.30
Strike160.00
Expiry date2025-01-17
Day's range119.65 - 119.65
Contract rangeN/A
Volume1
Open interest16
  • Yahoo Finance Video

    Amgen, DraftKings, Live Nation: Trending tickers

    Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith

  • Reuters

    Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data

    Novo Nordisk were last down 4.4% by 1022 GMT, having hit their lowest in two months earlier in the day. Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide, which, if approved, would compete Novo's Wegovy and Eli Lilly's Zepbound. "Novo's share price today is certainly factoring in some negative reaction to Amgen's positive commentary on MariTide development yesterday," Kepler Cheuvreux analyst David Evans said, but added that "a continued negative reaction to results and pricing concerns yesterday is likely also a smaller part of the move today".

  • Bloomberg

    Amgen Soars as CEO Gives Update on Experimental Obesity Drug

    (Bloomberg) -- Amgen Inc.’s shares soared after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide. Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineApple Rallies on Upbeat Forecast, Record-Setting BuybackTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesIn Jamie Dimon's America, the Stock Market Has